Bordetella pertussis is the etiological agent of whooping cough, an infection of the human respiratory tract. The disease is particularly severe in young children and may lead to neurological disorders and death (48) . The impact of pertussis morbidity and mortality on health is usually underestimated because of underreporting; however, 60,000,000 cases and more than 500,000 deaths per year are estimated to have a pertussis etiology or to be pertussis related (30) . The prevalence of pertussis in countries where vaccination is not mandatory is very high, with 95% of the sera of 17-to 19-year-old individuals containing antibodies against pertussis (16) .
In developed countries, the incidence of whooping cough has been reduced largely by mass immunization with a heat-killed whole-cell vaccine (10) . The benefits associated with this vaccine clearly outweigh the risks of rare but severe adverse effects, but nevertheless, public concern about safety and immunogenicity has resulted in decreased vaccination rates (22, 29) . Moreover, the efficacy of the whole-cell vaccine has been questioned in a few countries such as the United States because, although immunization rates are high, between 30 ,000 and 125,000 cases of pertussis have occurred annually (43) . Therefore, a new generation of nontoxic and highly immunogenic vaccines, consisting of well-defined components, is urgently needed. Several virulence factors of B. pertussis have been considered for inclusion in defined acellular vaccines, and detoxified pertussis toxin (PT) and filamentous hemagglutinin (FHA) are prime candidates (27, 34) . Conventional vaccines administered by the parenteral route seem to primarily elicit humoral immunity, and the secretory antibody responses are poor (17, 41, 44) . B. pertussis bacteria, however, infect the body through the respiratory tract mucosal membrane, and specific immunoglobulin A (IgA) is elicited after natural infec-* Corresponding author.
tion (44) . Such antibodies may well protect the host from both colonization and disease. It would, thus, seem worthwhile to explore means of stimulating mucosal immunity of airways and to evaluate its utility in protecting from infection and disease.
Liposomes have been successfully used as delivery systems for drugs, antigens, hormones, and genetic material (18) . Promising results have also been obtained following immunization with liposome-associated antigens; the oral (3, 19, 35, 37, 47) and parenteral (4, 8, 13, 24, 25, 38, 39, 42) routes have been used for antigens of parasites (4, 24, 25, 37, 39) , viruses (13, 32) , and bacteria (3, 8, 19, 35, 38, 42, 47) . Their potential as adjuvants has been demonstrated in several studies, in which the use of liposome-associated antigens resulted in protective immunity (4, 8, 19, 24, 25, 37, 39, 42) or at least cell-mediated (8) and humoral responses (3, 13, 38) . The adjuvanticity of liposomes seems to depend on several factors including vesicle size and structure, lipid constitution, surface charge, antigen localization, the animal species immunized, route of immunization, and the distribution and number of lamellae. The association of orally administered antigens with liposomes enhances their absorption, targeting them to processing cells, and favors their presentation to T cells and uptake into regional lymph nodes. This process improves the induction of humoral, secretory, and cell-mediated immune responses (1, 2, 18, 45) .
In the present report, we describe the ability of FHA-and PT-coated liposomes to induce specific systemic or secretory immune responses following oral immunization of mice.
MATERIALS AND METHODS
Preparation of antigen-coated liposomes. FHA was purified from B. pertussis Tohama as previously described by Sato et al. (40) , and PT was kindly supplied by S. Cryz (Swiss Serum and Vaccine Institute, Berne, Switzerland) and detoxified as described by Munoz et 30 . Mice that had been deprived of water for 6 to 8 h were orally given 50 ,ul of vaccine diluted in PBS and an equal volume of 3% sodium bicarbonate in PBS, pH 8.0, which was added immediately before in order to neutralize gastric acidity. The animals were anesthetized with ether and sacrificed by cervical dislocation 10 days after the booster. The blood samples were collected by cutting the brachial artery, and the serum was separated and stored at -20°C. Lung wash samples were collected by pertracheal cannulation and gentle washing with 0.7 ml of ice-cold PBS containing 2 mM phenylmethylsulfonyl fluoride as a protease inhibitor. About 0.5 ml of lung wash was recovered from each mouse, centrifuged at 4°C at 10,000 x g for 5 min to remove debris, and stored at -20°C.
Determination of specific antibodies against FEIA and PT. For the determination of class-specific antibodies against FHA and PT present in serum and lung washes, enzymelinked immunosorbent assays (ELISA) were performed as follows. Nunc Maxisorp Immunomodule 96-well plates were coated with FHA or PT diluted in 0.1 M NaHCO3 (pH 9.6) at 60 ng in 50 ,lI per well and incubated at 4°C overnight. The wells were blocked with 100 ,u of 10% fetal calf serum (ICN-Flow Biomedicals Societa per Azioni MI, Cassina de' Pecchi, Italy) in PBS for 2 h at 37°C. Plates were subsequently washed three times with PBS, and a 100-,ul serum sample diluted 1:50 or lung wash sample diluted 1:10 in 10% fetal calf serum in PBS was added to each well. After 60 min at 37°C, the plates were again washed, 100 pI of alkaline phosphatase-conjugated goat anti-mouse antibodies for IgG, IgM, or IgA heavy chains (Southern Biotechnology Associates, Inc.) diluted 1:500 in 10% fetal calf serum in PBS was added to each well, and the mixtures were incubated for 2 h at 37°C. The plates were again washed and then developed by the addition of 100 pl of the substrate solution (10 mg of p-nitrophenylphosphate disodium salt per ml in diethanolamine buffer, pH 9.8) per well. After 30 min at room temperature, the reaction was stopped by the addition of 50 pI of 3.0 M NaOH, and the A405 was determined with a Titretek (226 to 262) nm, respectively. These data suggest that the incorporation of FHA and PT into the liposomes does not significantly affect the average diameter of the liposomes.
Western blot analysis of liposomes containing FHA and PT.
The presence of FHA and PT in the vesicles was confirmed by Western blot analysis using the P12H3 monoclonal antibody (Fig. 1, lanes 2, 3, and 4 ) and the cocktail of hybridoma supernatants against PT subunits Si to 4 ( Fig. 1, lanes 2 , 5, and 6). No differences in FHA content between free FHA and FHA-coated liposomes (Fig. 1, lanes 3 and 4) were detected. On the other hand, differences between free PT and liposome-incorporated PT were evident (Fig. 1 (Fig. 1, lane 2) .
Immunoelectron-microscopic analysis of liposomes containing FHA and PT. Electron microscopy of the uncoated, FHA-coated, and PT-coated liposomes revealed that the liposomes were multilamellar and varied in size ( Fig. 2A, B , and C and 3A). The differences in size were greater than those shown by Coulter analysis. This could be due in part to either storage after synthesis or the methods used for electron microscopy. Moreover, the FHA-and PT-coated liposomes exhibit a morphological appearance different from that of the uncoated liposomes (compare Fig. 2A Fig. 2D with 3B ). Since the label intensity was sometimes only slightly above the background level, we have undertaken to demonstrate by postembedding labeling that PT can be detected on the liposome membrane. The former method allows only for the detection of antigenic reactive sites which stick out of the liposomes but not of those which reside on the inner side of the liposome membrane. In Fig. 3D , a liposome which exhibits a label around the membrane is depicted, demonstrating that PT is incorporated in the external membrane. In control experiments ( Fig. 2F and 3C) , only a very few gold particles could be detected. Antibody responses specific for B. pertussis FHA and PT in vaccinated mice. Both free FHA and PT and PT-and FHA-coated liposome prototype vaccines elicited specific serum and mucosal antibody responses (Fig. 4 and 5 antibody responses were obtained ( Fig. 4A and B) . The adjuvanticity of the liposome-based system was confirmed for FHA by the presence of antibody responses in mice immunized with FHA-coated liposomes that were approximately three times higher than the responses in mice immunized orally with free protein (Fig. 4) . The differences in antibody levels between mice immunized with FHA-coated liposomes and those immunized with free protein were statistically significant (P c 0.05). Simultaneous vaccination with FHA and PT, both free and liposome associated, did not affect anti-FHA antibody responses. The levels of FHAspecific IgM detected in lung wash samples were not significant (P > 0.05).
Similar results were obtained by immunization with PT ( Fig. 5A and B that stimulate efficient responses at the mucosal level which block infection. Secretory IgA and specific IgG (derived from serum by transudation through capillary vessels and being the predominant Ig in the lower respiratory tract) may interfere with the early events of bacterial attachment and colonization and thereby facilitate the eradication of the disease.
The site of antigen processing influences the Ig class profile of the immune response elicited. In fact, the secretory IgA response is typical of antigen administration by oral route (2, 6, 19, 23, 26, 45) . The specialized M cells which cover the Peyer's patches pass antigenic material to lymphocytes below the epithelium, where the processed antigens are presented to IgA precursor B cells. These B cells travel via the lymphatic system to the different mucosae and then give rise to IgA-secreting plasma cells. T lymphocytes may also acquire their homing pattern in the Peyer's patches (45) .
B. pertussis whole-cell vaccine given orally was demonstrated to be as effective as parenterally administered vaccine (9) . We have recently demonstrated specific lung mucosal responses against FHA and the S1 subunit of PT after oral immunization with recombinant aroA mutants of Salmonella spp. (20, 49 The immunizations were administered orally, mimicking the method which could be used in human oral vaccines. Therefore, we cannot rule out partial contributions to the elicited immune responses from other mucosa-associated immune tissues (i.e., nasal, salivary, and/or esophageal) in addition to those of gut-associated tissues.
The liposome system can be used to deliver multiple antigens including the 69-kDa outer membrane protein of B. pertussis, which was recently demonstrated to be an important protective antigen (33) . Escherichia coli strains which express recombinant FHA (21), Bordetella sp. strains which overproduce PT (50, 52) , and methods for the genetic detoxification of PT (36, 52) are now available and will facilitate the production of high yields of nontoxic, fully antigenic components for liposome-based subunit vaccines. In fact, multivalent vaccines which could replace the old DTP vaccine in infant vaccination regimes can be envisaged, as enhancement of the primary and secondary immune responses has resulted from diphtheria toxoid association with liposomes (1).
The mechanisms which mediate protection against B. pertussis infection are not clearly understood. Humoral and cellular responses following parenteral immunization do not always correlate (36) . Moreover, cell-mediated immune responses are believed to be important in vivo for protection against whooping cough disease (7, 15). As liposomes are known to induce cell-mediated immunity, it will be of interest to determine whether the delivery systems used in this study induce cell-mediated responses to FHA and PT in addition to the documented antibody responses.
The immune responses elicited following immunization with FHA-and PT-coated liposomes reported in this work suggest the usefulness of this delivery system in the development of oral vaccines against whooping cough. However, the system could be further enhanced by the incorporation of other products known to have adjuvant activity, which may have additive or synergistic effects on secretory-IgA priming (35, 38) , and/or administration of vitamin A, which may improve the immune responses after oral vaccination (2) . Moreover, other aspects, including the length of the immunity obtained, optimal vaccination schedule, and protection after challenge, must be investigated also.
The use of liposomes as a delivery system for subunit vaccines to induce immune responses distal to the site of entry are very promising. The oral route may reduce or eliminate the most frequent local side effects associated with whooping cough vaccines; then, adjuvanticity may increase both cell-mediated and humoral immune responses. Liposomes are chemically stable, simple to manufacture, and biodegradable; toxicity was not reported after liposomes were used in phase I and II trials (1, 18) . Moreover, the inexpensive raw materials used to produce the liposomes will contribute to reduced production costs. The oral administration of vaccines is in any case associated with a major cost saving vis-a-vis parenteral vaccination and is a key aspect of major vaccination programs, particularly in rural settings, where health care delivery is very expensive.
